| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
MCAAD-3 targets amyloid-β (Aβ) polymers, specifically Aβ aggregates and plaques in the brain. It has a strong affinity for Aβ polymers (Ki >106 nM). The probe's ability to cross the blood-brain barrier allows it to reach Aβ deposits in the brain. By binding to Aβ aggregates, MCAAD-3 enables the visualization of amyloid pathology using near-infrared imaging techniques.
|
|---|---|
| ln Vitro |
In vitro, MCAAD-3 demonstrates high binding affinity for Aβ polymers with a Ki >106 nM. The compound's near-infrared fluorescence properties offer deep tissue penetration and low background interference. Standard in vitro assays include binding studies using synthetic Aβ peptides or Aβ aggregates extracted from brain tissue. Fluorescence intensity is measured to assess binding affinity. The probe's specificity for Aβ over other proteins is confirmed using competitive binding assays with unlabeled compounds or other amyloid-binding dyes.
|
| ln Vivo |
In vivo, MCAAD-3 enables noninvasive visualization of Aβ plaques in vivo. It effectively labels amyloid deposits in transgenic mouse models of Alzheimer's disease. The probe's blood-brain barrier permeability allows it to reach Aβ deposits in the brain. Its near-infrared fluorescence properties support longitudinal studies of Aβ pathology. MCAAD-3 is a powerful tool for neurodegenerative research and early diagnostic imaging. However, comprehensive pharmacokinetic and pharmacodynamic studies are limited.
|
| Enzyme Assay |
For non-cell-based receptor binding assays, MCAAD-3 can be evaluated using purified Aβ aggregates or synthetic Aβ peptides. Binding affinity is assessed by incubating increasing concentrations of the probe with immobilized Aβ aggregates and measuring fluorescence intensity. Competitive binding assays are performed using unlabeled Aβ or other amyloid-binding compounds to assess specificity. Ki values are calculated from displacement curves using nonlinear regression analysis. The probe's near-infrared fluorescence properties (excitation/emission in the NIR range) allow for sensitive detection of binding.
|
| Cell Assay |
For in vitro cellular assays, cells expressing amyloid precursor protein (APP) or treated with exogenous Aβ are used to assess MCAAD-3 binding. Cells are incubated with the probe and fluorescence is measured using a fluorescence plate reader or imaging system. For specificity testing, cells are co-incubated with the probe and competing compounds. For phagocytosis or clearance assays, microglial cells are incubated with Aβ aggregates and the probe to assess the effects of imaging on Aβ clearance. The probe's low background interference supports high signal-to-noise ratio imaging.
|
| Animal Protocol |
For in vivo animal studies, MCAAD-3 is administered to transgenic mouse models of Alzheimer's disease via intravenous injection. Near-infrared imaging is performed at various time points post-injection to visualize Aβ plaques in the brain. Fluorescence signal intensity is measured and correlated with amyloid burden assessed by immunohistochemistry. The probe's ability to label Aβ plaques is confirmed by ex vivo brain imaging and histological analysis. Dosing regimens vary depending on the specific model and imaging protocol.
|
| ADME/Pharmacokinetics |
MCAAD-3 has a molecular weight of 282.34 and a molecular formula of C17H18N2O2. Its near-infrared fluorescence properties offer deep tissue penetration and low background interference, supporting longitudinal studies of Aβ pathology. The probe has excellent blood-brain barrier permeability. It is supplied in high purity (≥95%). The compound should be stored according to the manufacturer's recommendations. It is for research use only and not for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of MCAAD-3 has not been extensively reported. As a near-infrared imaging probe, it is expected to have a favorable safety profile for research applications. The compound is for research use only and not for human consumption. Standard toxicological evaluation would include acute toxicity studies, as well as assessment of effects on the central nervous system and other organ systems. The probe's low background interference supports its use in imaging applications without significant toxicity concerns.
|
| References |
[1]. Fu H, et al. Evaluation of molecules based on the electron donor-acceptor architecture as near-infrared β-amyloidal-targeting probes. Chem Commun (Camb). 2014 Oct 14;50(80):11875-8.
|
| Additional Infomation |
MCAAD-3 is a near-infrared (NIR) imaging probe specifically designed for detecting amyloid-β (Aβ) aggregates in the brain. It has excellent blood-brain barrier permeability and a high binding affinity for Aβ polymers (Ki >106 nM). MCAAD-3 enables noninvasive visualization of Aβ plaques in vivo and can label Aβ plaques in the brains of transgenic mice. It is a powerful tool for neurodegenerative research and early diagnostic imaging.
|
| Molecular Formula |
C17H18N2O2
|
|---|---|
| Molecular Weight |
282.337024211884
|
| Exact Mass |
282.136
|
| CAS # |
1625629-51-7
|
| PubChem CID |
137699582
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.5
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
21
|
| Complexity |
472
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(C)C1=CC=C(C=C1)/C=C/C=C/C=C(/C#N)\C(=O)OC
|
| InChi Key |
VUICGFIMDGFKFH-FGHSSWIZSA-N
|
| InChi Code |
InChI=1S/C17H18N2O2/c1-19(2)16-11-9-14(10-12-16)7-5-4-6-8-15(13-18)17(20)21-3/h4-12H,1-3H3/b6-4+,7-5+,15-8-
|
| Chemical Name |
methyl (2Z,4E,6E)-2-cyano-7-[4-(dimethylamino)phenyl]hepta-2,4,6-trienoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 10 mg/mL (35.42 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5418 mL | 17.7091 mL | 35.4183 mL | |
| 5 mM | 0.7084 mL | 3.5418 mL | 7.0837 mL | |
| 10 mM | 0.3542 mL | 1.7709 mL | 3.5418 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
